2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Stomach Neoplasms
7
Esophageal Neoplasms
4
Gastrointestinal Neoplasms
3
Pancreatic Neoplasms
2
Neoplasm Metastasis
2
Adenocarcinoma
2
Solid Tumor
1
Rectal Neoplasms
1
Patients With Advanced or Metastatic Solid Tumors
1
Pathologic Complete Response
1
Neoplasms, Unknown Primary
1
Nasopharyngeal Carcinoma
1
Locally Advanced Gastric Adenocarcinoma
1
Hand-Foot Syndrome
1
Colorectal Neoplasms
1
Colonic Neoplasms
1
Biliary Tract Neoplasms
1
Bile Duct Neoplasms
1
Adenocarcinoma Of Esophagus
1
Interventions
Gemcitabine
40
Cisplatin
24
Capecitabine
21
Fluorouracil
19
Oxaliplatin
17
Leucovorin
14
pembrolizumab
9
Irinotecan
8
Radiotherapy
7
Erlotinib Hydrochloride
7
durvalumab
6
Sorafenib
4
Photochemotherapy
4
Magnetic Resonance Spectroscopy
4
Carboplatin
4
trametinib
3
Trastuzumab
3
Radiofrequency Ablation
3
Long-Term Synaptic Depression
3
Interleukin-12 Subunit p35
3
Filgrastim
3
Drug Therapy
3
Dihematoporphyrin Ether
3
Dexamethasone
3
Cholangiopancreatography, Endoscopic Retrograde
3
Chemotherapy, Adjuvant
3
trifluridine tipiracil drug combination
2
tivozanib
2
tislelizumab
2
spartalizumab
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Bile Duct Neoplasms
×
tegafur-gimeracil-oteracil
×
Clear all
NCT01845337
2023-05-12
TOFFEE
University of Edinburgh
Phase 2
Completed
59 enrolled